Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 9, Issue 3, Pages -
Publisher
Springer Nature
Online
2019-02-19
DOI
10.1038/s41408-019-0185-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
- (2018) Masahiro Takeuchi et al. IMMUNOLOGY LETTERS
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
- (2017) Xinxin Zhu et al. Journal of Gynecologic Oncology
- Checkpoint inhibitors in hematological malignancies
- (2017) Chi Young Ok et al. Journal of Hematology & Oncology
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment
- (2017) Lekha Mikkilineni et al. SEMINARS IN ONCOLOGY
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- Immune checkpoint therapy for non-small-cell lung cancer: an update
- (2016) Bing Xia et al. Immunotherapy
- Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation
- (2016) Katrin Birkenmeier et al. INTERNATIONAL JOURNAL OF CANCER
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells
- (2016) Xin Liu et al. Scientific Reports
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-Linking of B7-H1 on EBV-Transformed B Cells Induces Apoptosis through Reactive Oxygen Species Production, JNK Signaling Activation, and fasL Expression
- (2014) Y. S. Kim et al. JOURNAL OF IMMUNOLOGY
- Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
- (2013) P. Greaves et al. BLOOD
- Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer
- (2013) XIAO SONG et al. ONCOLOGY REPORTS
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype
- (2008) M Vockerodt et al. JOURNAL OF PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More